Hinge Health Expands Into Surgery, Raising Growth Targets

Forward-Looking Analysis

Wall Street analysts maintain a consensus "Moderate Buy" rating for Hinge Health, with an average 12-month price target of $74.33, representing approximately 13.10% upside from recent trading levels. Recent analyst actions indicate strong bullish sentiment; Truist Financial raised its price target to $85.00, citing growth outlook, while Citizens JMP increased its target to $96.00. Neutopia also raised its target to $76.00, and Stifel reiterated its buy rating, highlighting expansion into surgical care as a key driver. Earnings growth is projected to accelerate significantly, with estimates showing earnings per share rising from $1.37 to $1.85 in the coming year, a 35.04% increase. The company raised its 2026 outlook ahead of its Investor Day, signaling confidence in its financial trajectory. Despite a current negative Price-to-Earnings ratio of -6.07, indicating recent net losses, the high analyst coverage of 16 research reports in the past 90 days underscores significant institutional interest. The consensus price target of $86.07 suggests a 15.0% potential upside, with the highest individual target reaching $95.00. These projections reflect expectations that the integration of AI-driven care and new service lines will enhance revenue streams and improve long-term profitability metrics.

Historical Performance Review

Hinge Health delivered robust results in 2026Q1, reporting revenue of $182.31 million, which demonstrated strong top-line growth. The company achieved a net income of $35.13 million, reflecting effective cost management and operational leverage. Earnings per share stood at $0.43, exceeding market expectations and indicating improving unit economics. Furthermore, gross profit reached $154.23 million, highlighting the scalability of its digital musculoskeletal care platform. These figures collectively signal a transition toward sustainable profitability, with significant improvements in both revenue generation and margin expansion compared to previous periods.

Additional News

Hinge Health is expanding its clinical offerings by adding surgery to its HingeSelect platform, creating a fully integrated musculoskeletal care ecosystem. This move allows the company to leverage its AI-driven care platform into migraine management and post-surgical rehabilitation, raising growth and margin targets. The company raised its 2026 financial outlook ahead of its Investor Day, emphasizing confidence in its strategic direction. Analyst coverage remains intense, with Truist Financial, Citizens JMP, and Neutopia recently raising price targets to $85.00, $96.00, and $76.00 respectively, citing strong growth prospects. The stock has seen significant insider selling activity, with major shareholders and the Chairman selling substantial shares in July 2026, totaling nearly $300 million in sales. However, institutional sentiment appears mixed, with minimal overall institutional ownership despite high analyst ratings. The company’s market capitalization stands at $5.07 billion, with a 52-week trading range between $30.08 and $66.55. Short interest has decreased by 7.03%, suggesting improving investor sentiment. The platform continues to partner with major employers and health plans to deliver end-to-end digital health solutions, aiming to reduce reliance on invasive interventions and opioid prescriptions through data-analyzed outcomes.

Summary & Outlook

Hinge Health demonstrates improving financial health, evidenced by positive Q1 net income of $35.13 million and strong gross margins. Growth catalysts include the expansion into surgical care and migraine management, which analysts believe will drive margin expansion and revenue acceleration. While insider selling raises minor governance concerns, the overwhelming analyst consensus of "Moderate Buy" and raised price targets reflect confidence in the company's scalable digital model. The projected 35% earnings growth indicates a clear path to sustained profitability. Given the strategic product expansions and positive analyst revisions, the outlook is cautiously bullish, though investors should monitor execution risks in the new surgical verticals. The company is well-positioned to capture market share in the digital MSK care sector, supported by strong institutional interest and favorable long-term growth projections.